International Market ExpansionThe Allurion Balloon has been cleared to resume sales in France, which historically accounted for ~15% of sales, potentially providing a meaningful tailwind to ALUR's growth trajectory.
Regulatory ProgressThe safety outcomes in Audacity appear very favorable and unambiguous, with the rate of serious adverse events in the Allurion balloon group reported as 3.1%, the lowest SAE rate in a pivotal FDA trial of a liquid-filled IGB for weight loss.